**Core Concept**
Mild von Willebrand factor (vWF) deficiency is a bleeding disorder characterized by impaired platelet adhesion and aggregation at the site of injury. In patients with vWF deficiency, prophylactic measures are crucial to prevent excessive bleeding during invasive procedures such as tooth extraction.

**Why the Correct Answer is Right**
In patients with mild vWF deficiency, the primary goal of prophylaxis is to enhance platelet adhesion and aggregation. Desmopressin (DDAVP) is a synthetic analogue of vasopressin that stimulates the release of vWF and factor VIII from endothelial cells, thereby improving platelet function. This is particularly beneficial for patients with mild vWF deficiency, as it can effectively reduce the risk of bleeding during procedures.

**Why Each Wrong Option is Incorrect**
**Option A:** Tranexamic acid is an antifibrinolytic agent that inhibits the breakdown of fibrin clots, but it does not directly address the underlying issue of impaired platelet adhesion and aggregation in vWF deficiency. It may be used as an adjunct therapy, but it is not the primary treatment for prophylaxis.
**Option B:** Platelet transfusion is not indicated for vWF deficiency, as it does not address the underlying issue of impaired vWF function. Platelet transfusion may even worsen the bleeding risk due to the development of alloantibodies.
**Option C:** Factor VIII replacement therapy is not indicated for vWF deficiency, as the primary issue is impaired vWF function, not factor VIII deficiency.

**Clinical Pearl / High-Yield Fact**
Desmopressin is a useful prophylactic agent for patients with mild vWF deficiency, but it is not effective in patients with type 3 vWF deficiency or those who have undergone splenectomy.

**Correct Answer:** A. Desmopressin (DDAVP)